Recursion Pharmaceuticals
RXRX
75 hedge funds and large institutions have $1.71B invested in Recursion Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 75 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
27.91% more ownership
Funds ownership: 0% → 27.91% (+28%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$548M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$114M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$79.4M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$70.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$65.5M |
Top Sellers
RXRX Hedge Fund Activity: Q2 2021 in Review
75 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q2 2021, worth a combined $1.71B.
Buyers outnumbered sellers: 75 funds opened new RXRX positions and 0 closed out — a net gain of 75 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baillie Gifford & Co, opening a new position worth an estimated $548M.
- 75 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $1.71B of Recursion Pharmaceuticals stock for Q2 2021.
- 75 funds opened new Recursion Pharmaceuticals positions in Q2 2021 and 0 closed out, a net change of +75 holders.
- The largest Recursion Pharmaceuticals buyer in Q2 2021 was Baillie Gifford & Co, an estimated $548M added.
Based on aggregated 13F filings for Q2 2021.